Zenas BioPharma Entered into a License and Collaboration Agreement with BMS to Develop and Commercialize Obexelimab for Autoimmune Diseases
Shots:
- Zenas will receive a $50M up front & an equity investment from BMS, additional fees upon achievement of milestones along with royalties on net sales of obexelimab in the licensed territory. BMS to get an exclusive right to develop & commercialize obexelimab in the licensed territory
- Both companies collaborated to develop & commercialize obexelimab in Japan, South Korea, Taiwan, Singapore, Hong Kong and Australia. The collaboration uses BMS’ expertise in immune-mediated diseases to bring innovative immunology-based therapies to patients globally
- Obexelimab, a bifunctional, non-cytolytic, humanized mAb & is currently being studied as an SC inj. in a P-III trial for IgG4-RD & also being studied in a P-II/III trial for warm antibody Auto-Immune Hemolytic Anemia
Ref: Globenewswire | Image: Zenas BioPharma
Related News:- Zenas Acquires Exclusive WW Rights of Xencor's obexelimab for the Treatment of Autoimmune Diseases
PharmaShots! Your go-to media platform for customized news ranging for multiple indications. For more information connect with us at connect@pharmashots.com
Click here to read the full press release
Tags
Neha is a Senior Editor at PharmaShots. She is passionate and very enthusiastic about recent updates and developments in the life sciences and pharma industry. She covers Biopharma, MedTech, and Digital health segments along with different reports at PharmaShots. She can be contacted at connect@pharmashots.com.
